Jpmorgan Chase & CO Maxcyte, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Maxcyte, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 241,572 shares of MXCT stock, worth $898,647. This represents 0.0% of its overall portfolio holdings.
Number of Shares
241,572
Previous 240,679
0.37%
Holding current value
$898,647
Previous $1.13 Million
10.52%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding MXCT
# of Institutions
126Shares Held
62MCall Options Held
2.4KPut Options Held
2.1K-
Black Rock Inc. New York, NY7.23MShares$26.9 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY6.56MShares$24.4 Million0.98% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.17MShares$23 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.35MShares$19.9 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$18.8 Million6.7% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $378M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...